Jetema's 'e.p.t.q.' Officially Approved for Product Registration in China

Jetema, a global medical aesthetics company, announced on April 28 that its hyaluronic acid (HA) filler product, e.p.t.q. (Epitique), has recently received official Class III medical device approval from the National Medical Products Administration (NMPA) of China.

This approval marks Jetema's official entry into China, one of the world's largest aesthetic medical markets. Epitique is one of Jetema's flagship filler lines and has already received high praise in both domestic and international markets. By obtaining Class III approval, the highest level of medical device certification from the NMPA, its safety and efficacy have been officially recognized.

Jetema plans to collaborate with local partners to establish a legal and transparent distribution structure based on the NMPA product approval. This is expected to serve as an important foundation for securing long-term brand trust and stable market establishment in the future.

A Jetema representative stated, "In the past, some Korean aesthetic medical products suffered damage to their brand image due to illegal distribution channels. In contrast, Jetema has officially entered the market through the Chinese government's formal approval process, and we aim to establish ourselves as a premium filler brand in China based on trust in our quality and safety."

Previously, in February, Jetema's subsidiary JETEMA SHANGHAI signed an exclusive five-year promotional contract for Epitique with ZUOYI BIO (formerly Huadong Aesthetics), a leading Chinese aesthetics distributor. The total contract amount is $30.45 million (approximately KRW 43.5 billion). Jetema expects sales to increase by more than KRW 40 billion as a result.

Huadong Ningbo, the predecessor of ZUOYI BIO, achieved the number one position in filler product sales in China through an exclusive contract with LG Life Sciences in 2013, recording sales that exceeded expectations. Based on this track record, Jetema also expects to achieve sales that surpass initial forecasts through this contract.

Jetema plans to realize long-term brand value beyond short-term results through official market entry procedures and trust-based partnerships.